A novel bioassay for thyroid-blocking immunoglobulins.

ABSTRACT:

Background

Thyroid-blocking immunoglobulins (TBI) are present in 10%-15% of patients with autoimmune thyroid disease (AITD). TBI affect thyroid function. The analytical performance of a novel TBI bioassay was evaluated.

Methods

Sera from AITD patients were tested with a cell-based TBI reporter bioassay (Thyretain^®) with the expression of a luciferase transgene as readout and a new "Turbo™" TBI bioassay with a readout based on a cyclic AMP-activated luciferase. All samples were also run on two TSH-R binding immunoassays. A Passing-Bablok regression, a Bland-Altman plot, and user/lot comparisons were performed. In addition, dose-response curves for Turbo and Thyretain were fitted using serial dilutions, and half-maximal and 80% inhibitory concentrations (IC_50</

SUBMITTER: George A 

PROVIDER: S-EPMC11554474 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature